A Genome-Wide Association Study of Survival in Patients with Sepsis - Hernandez-Beeftink, Tamara; Guillen-Guio, Beatriz; Lorenzo-Salazar, Jose M.; Corrales, Almudena; Suarez-Pajes, Eva; Feng, Rui; Rubio-Rodríguez, Luis A.; Paynton, Megan L; Cruz-Guerrero, Raquel; García-Laorden, M. Isabel; Prieto-González, Miryam; Rodríguez-Pérez, Aurelio; et al. (medRxiv, 2022)
Background Sepsis is a severe systemic inflammatory response to infections that is accompanied by organ dysfunction and has a high mortality rate in adult intensive care units (ICUs). Most genetic studies have identified gene variants associated with development and outcomes of sepsis focusing on biological candidates. We conducted the first genome-wide association study (GWAS) of 28-day survival in adult patients with sepsis.Methods This study was conducted in two stages. The first stage was performed on 687 European sepsis patients from the GEN-SEP network and 7.5 million imputed variants. Association testing was conducted with Cox regression models, adjusting by sex, age, and the main principal components of genetic variation. A second stage focusing on the prioritized genetic variants was performed on 2,063 ICU sepsis patients (1,362 European Americans and 701 African Americans) from the MESSI study. A meta-analysis of results from the two stages was conducted and significance was established at p<5.0×10−8. Whole-blood transcriptomic and functional annotations were evaluated on the identified genes and variants.Findings We identified three independent variants associated with reduced 28-day sepsis survival, including a missense variant in SAMD9 (hazard ratio [95% confidence interval]=1.64 [1.37-6.78], p=4.92×10−8). SAMD9 encodes a mediator of the inflammatory response to tissue injury that is overexpressed in peripheral blood of non-surviving sepsis patients compared to those surviving (p=2.18×10−3).Interpretation We performed the first GWAS of 28-day sepsis survival and identified novel variants associated with reduced survival. Our findings could allow the identification of novel targets for sepsis treatment and patient risk stratification.Evidence before this study Sepsis is defined as a life-threatening clinical syndrome of physiological, pathological, and biochemical abnormalities caused by a dysregulated host response to an infection, and with long-term physical, psychological, and cognitive disabilities. Many genetic studies have focused on identifying genetic risk factors associated with sepsis development and severity, but only four genome-wide association studies (GWAS) have been published to date. Three of them focused on sepsis mortality. The first study identified that common genetic variation in the FER gene associated with a reduced risk of death. The second study found variants associated with an increased risk of death in VPS13A, which is key in autophagic degradation. In the last study, variants of the CISH gene, involved in cytokine regulation, were associated with the risk of death. Nevertheless, there is a lack of GWAS focused on sepsis survival, which takes into account the probability estimates of death for each patient over time.Added value of this study To the best of our knowledge, we provide the results of the first GWAS of 28-day sepsis survival conducted to date. In this two-staged study, we identified three novel loci associated with reduced 28-day survival among sepsis patients. We identified one missense variant in SAMD9, which encodes a critical regulator in the inflammatory response and apoptosis. A significant upregulation of SAMD9 gene expression in whole blood was observed among non-surviving sepsis patients compared to those surviving. Associations were also found for one intergenic variant to SLC5A12\FIBIN and an intergenic variant to two non-coding RNAs (LINC00378\MIR3169).Implications of all the available evidence The identification of effective prognostic genetic markers in sepsis is a promising instrument for clinical practice. This study identified three novel genetic factors of fatal outcomes, all having interesting and important biological plausibly that could serve as novel targets for sepsis treatment. This knowledge is important to propose effective sepsis treatments and will be central in the development of personalized medicine approaches.Competing Interest StatementNJM reports funding to her institution from NIH related to this project; funding to her institution from Quantum Leap Healthcare Collaborative, Biomarck Inc, and Athersys Inc for work unrelated to this manuscript; and participation on the Scientific Advisory Board for Endpoint Health, Inc. She is a member of the Data Safety Monitoring Board for the Careful Ventilation in ARDS (CAVIARDS) trial and the Observational Study Monitoring Board for the SPIROMICS II study. The rest of the authors declare no competing interests.Funding StatementThis study was funded by Instituto de Salud Carlos III (CB06/06/1088; PI16/00049; PI17/00610; FI17/00177; PI19/00141; PI20/00876) and co-financed by the European Regional Development Funds, 'A way of making Europe' from the European Union; agreement OA17/008 with Instituto Tecnologico y de Energias Renovables (ITER) to strengthen scientific and technological education, training, research, development and innovation in Genomics, Personalized Medicine and Biotechnology; and by Cabildo Insular de Tenerife (CGIEU0000219140). LVW holds a GSK / Asthma + Lung UK Chair in Respiratory Research (C17-1). The research was partially supported by the NIHR Leicester Biomedical Research Centre; the views expressed are those of the author(s) and not necessarily those of the National Health Service (NHS), the NIHR, or the Department of Health. BG-G is supported by Wellcome Trust grant 221680/Z/20/Z. The MESSI cohort is funded by NIH NHLBI awards HL137006, HL137915, and HL155804 (NJM). The genotyping service of GEN-SEP was done at CEGEN-PRB3-ISCIII; it is supported by grant PT17/0019, of the PE I+D+i 2013-2016, funded by Instituto de Salud Carlos III and European Regional Development Fund. For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Drug Research from the Hospital Universitario de Canarias (Code: CHUNSC_2018-16) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.